LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Slēgts

32 -1.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

30.98

Max

32.75

Galvenie mērījumi
By Trading Economics
Ienākumi	-30M -30M
Pārdošana	-26M 77M
Peļņas marža	-38.823
Darbinieki	524
EBITDA	-12M -8M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+101.25% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-7.8M 1.7B
Iepriekšējā atvēršanas cena	33.54
Iepriekšējā slēgšanas cena	32

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

27.895 / 30.16 Atbalsts un pretestība

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. marts 18:43 UTC

Galvenie ziņu notikumi

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026. g. 3. marts 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026. g. 3. marts 23:45 UTC

Tirgus saruna

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026. g. 3. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 3. marts 22:38 UTC

Galvenie ziņu notikumi

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026. g. 3. marts 22:16 UTC

Peļņas

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026. g. 3. marts 22:09 UTC

Peļņas

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026. g. 3. marts 22:06 UTC

Peļņas

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026. g. 3. marts 22:05 UTC

Peļņas

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026. g. 3. marts 22:03 UTC

Peļņas

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 3. marts 21:45 UTC

Galvenie ziņu notikumi

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026. g. 3. marts 21:37 UTC

Peļņas

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026. g. 3. marts 21:26 UTC

Galvenie ziņu notikumi

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026. g. 3. marts 20:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026. g. 3. marts 20:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026. g. 3. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold and Silver Drop as Energy Surges -- Market Talk

2026. g. 3. marts 18:43 UTC

Peļņas

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026. g. 3. marts 18:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026. g. 3. marts 18:14 UTC

Peļņas

How Long Can Anthropic Play Defense? -- WSJ

2026. g. 3. marts 17:41 UTC

Galvenie ziņu notikumi

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026. g. 3. marts 17:36 UTC

Galvenie ziņu notikumi

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026. g. 3. marts 17:28 UTC

Iegādes, apvienošanās, pārņemšana

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

101.25% augšup

Prognoze 12 mēnešiem

Vidējais 65.75 USD 101.25%

Augstākais 100 USD

Zemākais 38 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.